Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia
Top Cited Papers
Open Access
- 8 November 2005
- journal article
- research article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (1), 97-103
- https://doi.org/10.1016/j.jhep.2005.10.003
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Hepatocellular carcinoma and hepatitis C in the United StatesHepatology, 2002
- Natural history of chronic hepatitis CHepatology, 2002
- Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 2001
- A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis CHepatology, 2001
- Hepatitis C Virus InfectionNew England Journal of Medicine, 2001
- Peginterferon Alfa-2a in Patients with Chronic Hepatitis CNew England Journal of Medicine, 2000
- EASL International Consensus Conference on Hepatitis C Paris, 26–28 February 1999Journal of Hepatology, 1999
- Prognosis of Chronic Hepatitis C: Results of A Large, Prospective Cohort StudyHepatology, 1998
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998